绝经后如何?WHAM研究:绝经前降低风险双侧输卵管卵巢切除术后12个月的心血管代谢风险
这项前瞻性观察研究纳入95例计划行降低风险双侧输卵管卵巢切除术(RRBSO)的绝经前女性和99例保留卵巢的对照,测量基线及12个月时的心血管代谢指标。结果显示12个月后多数指标无显著变化,但RRBSO组体重和BMI轻度增加,且未使用激素治疗者腰围增加更明显(4.3 cm vs 1.3 cm,P<0.001)。
要点
- RRBSO后12个月心血管代谢指标总体稳定,但体重和BMI有轻度上升趋势。
- 术后未启动激素治疗者腰围平均增加4.3 cm,显著高于激素治疗者的1.3 cm。
- 激素治疗可能有助于减缓RRBSO后腰围增加,但需结合个体情况权衡利弊。
核心结论
- RRBSO后12个月心血管代谢风险标志物基本无变化,激素治疗可能预防腰围增加。
研究设计与样本
- 前瞻性观察研究,纳入95例计划行RRBSO的绝经前女性和99例年龄相近的保留卵巢对照。
- 在基线和12个月时测量血压、BMI、腰臀围、血脂、高敏C反应蛋白、血糖和胰岛素,并计算HOMA-IR。
主要发现
- 配对t检验显示RRBSO组BMI(p=0.037)和体重(p=0.042)增加,腰围(p<0.001)和腰臀比(p=0.009)增加幅度大于对照组,但调整基线值后不显著。
- RRBSO后60%启动激素治疗(HT)。
- 非HT使用者腰围平均增加4.3 cm(95%CI 2.0-6.5),HT使用者增加1.3 cm(95%CI -0.2-2.7),组间差异显著(p<0.001),调整基线值后仍显著(p=0.02)。
- 12个月时非HT使用者平均腰围比HT使用者大2.94 cm。
临床怎么用
- RRBSO术后应监测体重和腰围变化,尤其关注未使用激素治疗者。
- 对于RRBSO后绝经前女性,可评估激素治疗对中心性肥胖的潜在预防作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To prospectively measure cardiometabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy (RRBSO) compared to a similar age comparison group, and the effects of Hormone Therapy (HT) on cardiometabolic risk. METHODS: Prospective observational study of 95 premenopausal women planning RRBSO and 99 comparisons who retained their ovaries. At baseline and 12 months, blood pressure (BP), Body Mass Index (BMI), waist and hip circumference, fasting total, HDL and LDL cholesterol, triglycerides, high-sensitivity C-reactive protein, glucose and insulin were measured and HOMA-IR was calculated. Chi-square tests, t-tests and adjusted logistic regression models were used to compare groups. RESULTS: Baseline cardiometabolic phenotypes were similar between groups but more RRBSO participants were overweight/obese with higher waist/hip ratios. By 12 months, BP and cardiometabolic phenotypes were largely unchanged. Paired t-tests showed statistically significant increases in BMI (p = 0.037) and weight (p = 0.042) and larger increases in waist circumference (p < 0.001) and waist-hip ratio (p = 0.009) after RRBSO vs comparisons. However, these were not significant when adjusted for baseline values. After RRBSO 60% initiated Hormone Therapy (HT). Paired t-tests demonstrated that non-HT users had a significantly greater mean increase in waist circumference of 4.3 cm (95% CI 2.0-6.5) compared to 1.3 cm in HT users (95% CI -0.2-2.7, p < 0.001), which remained significant when adjusted for baseline values (p = 0.02). At 12 months, mean waist circumference was 2.94 cm greater in non-HT users compared to HT users. CONCLUSIONS: Cardiometabolic risk markers are largely unchanged 12 months after RRBSO. Hormone Therapy after RRBSO may prevent against an increase in waist circumference.
引用
- Hickey M, Moss KM, Mishra GD, et al. What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. Gynecol Oncol. 2021. PMID: 33972087. doi:10.1016/j.ygyno.2021.04.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。